-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將12個月目標股價下調10美元至412美元,主要原因是2027年預期每股收益的本益比為22.6倍,低於同業平均預期本益比24.6倍,但高於GD過去三年平均預期本益比18.6倍。我們將2026年預期每股盈餘下修0.18美元至16.77美元,2027年預期每股盈餘下修0.43美元至18.24美元。 GD的基本面依然強勁,總積壓訂單年增48%至1,310億美元,訂單出貨比高達2.1倍。海洋系統業務仍是主要的成長動力(營收成長21%),這主要得益於維吉尼亞級和哥倫比亞級潛艦計畫的推動。通用汽車(GD)正大力投資造船產能和彈藥生產,以滿足持續成長的需求。航空航太業務憑藉G700/G800生產效率的提升,實現了15%的強勁營業利潤率,但中東衝突抑制了近期訂單量。 22億美元的強勁現金流增強了資產負債表的穩健性。公司將2026財年全年每股收益預期上調至16.45美元至16.55美元,增強了對所有業務板塊執行力的信心,儘管複雜的國防項目仍面臨持續的供應鏈管理挑戰。
Related Articles
Argus Adjusts Price Target on Nasdaq to $103 From $98
Nasdaq (NDAQ) has an average rating of buy and mean price target of $110.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $91.54, Change: $-0.37, Percent Change: -0.40%
Argus Adjusts Price Target on IDEX to $250 From $240
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $470.05, Change: $-8.91, Percent Change: -1.86%